Artículo de revista
Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: Therapeutic implications
Fecha
2009Registro en:
Journal of Neurochemistry, Volumen 111, Issue 4, 2018, Pages 891-900
00223042
14714159
10.1111/j.1471-4159.2009.06325.x
Autor
Gaspar, Pablo A.
Bustamante, M. Leonor
Silva, Hernán
Aboitiz, Francisco
Institución
Resumen
Early models for the etiology of schizophrenia focused on dopamine neurotransmission because of the powerful anti-psychotic action of dopamine antagonists. Nevertheless, recent evidence increasingly supports a primarily glutamatergic dysfunction in this condition, where dopaminergic disbalance is a secondary effect. A current model for the pathophysiology of schizophrenia involves a dysfunctional mechanism by which the NMDA receptor (NMDAR) hypofunction leads to a dysregulation of GABA fast- spiking interneurons, consequently disinhibiting pyramidal glutamatergic output and disturbing the signal-to-noise ratio. This mechanism might explain better than other models some cognitive deficits observed in this disease, as well as the dopaminergic alterations and therapeutic effect of anti-psychotics. Although the modulation of glutamate activity has, in principle, great therapeutic potential, a side effect of NMDAR overactivation is neurotoxicity, which accelerates neuropathological alterati